Cargando…

Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis

OBJECTIVES: Our meta-analysis performed a systematic evaluation on the therapeutic efficacy and safety of tumour vaccines for the treatment of advanced non-small cell lung cancer (NSCLC). DESIGN: Systematic review and meta-analysis of randomised controlled trials (RCT). DATA SOURCES: PubMed, the Coc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Min, Cao, Jun-Xia, Liu, Yi-Shan, Xu, Bei-Lei, Li, Duo, Zhang, Xiao-Yan, Li, Jun-Li, Liu, Jin-Long, Wang, Hai-Bo, Wang, Zheng-Xu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401843/ https://www.ncbi.nlm.nih.gov/pubmed/25872936 http://dx.doi.org/10.1136/bmjopen-2014-006321

Ejemplares similares

Adoptive Immunotherapy of Cytokine-Induced Killer Cell Therapy in the Treatment of Non-Small Cell Lung Cancer
por: Wang, Min, et al.
Publicado: (2014)

Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review
por: Li, Lingling, et al.
Publicado: (2020)

Advances in CAR T cell immunotherapy for paediatric brain tumours
por: Rao, Padmashree, et al.
Publicado: (2022)

Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Liu, Ying, et al.
Publicado: (2021)

Clinical Efficacy of Tumor Antigen-Pulsed DC Treatment for High-Grade Glioma Patients: Evidence from a Meta-Analysis
por: Cao, Jun-Xia, et al.
Publicado: (2014)

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
por: Wang, Yunzhen, et al.
Publicado: (2023)

“Sandwich Therapy”—Immunotherapy Plus Concurrent Chemoradiotherapy for Advanced Esophagogastric Junction Carcinoma: Report of Two Cases and Literature Review
por: Wu, Lei, et al.
Publicado: (2022)

Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xu, Yanjun, et al.
Publicado: (2021)

Progression in immunotherapy for advanced prostate cancer
por: Liang, Hao, et al.
Publicado: (2023)

Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
por: Zhang, Xiaofei, et al.
Publicado: (2023)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy
por: Xiao, Mingshu, et al.
Publicado: (2022)

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma
por: Zhao, Li-ming, et al.
Publicado: (2023)

Tumour microenvironment landscape and immunotherapy response in bladder cancer decoded by stromal MOXD1 based on copper-related genes signature
por: Wang, Wenhao, et al.
Publicado: (2022)

Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Metabolomics profiling in prediction of chemo-immunotherapy efficiency in advanced non-small cell lung cancer
por: Mei, Lihong, et al.
Publicado: (2023)

Advances in the Study of CircRNAs in Tumor Drug Resistance
por: Wang, Song, et al.
Publicado: (2022)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

The emerging nanomedicine-based technology for non-small cell lung cancer immunotherapy: how far are we from an effective treatment
por: Peng, Lei, et al.
Publicado: (2023)

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer
por: Kang, Jin, et al.
Publicado: (2020)

Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to Immunotherapy in Patients With Metastatic Melanoma
por: Wang, Zhi-long, et al.
Publicado: (2020)

Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy
por: Jiang, Meilin, et al.
Publicado: (2020)

Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series
por: Zhao, Shuang, et al.
Publicado: (2021)

Immunotherapies of retinoblastoma: Effective methods for preserving vision in the future
por: Wang, Ling, et al.
Publicado: (2022)

Induction Therapy Followed by Surgery for Unresectable Thymic Epithelial Tumours
por: Wang, Shuai, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis
por: Wang, Jincheng, et al.
Publicado: (2022)

Toxicities of Immunotherapy for Small Cell Lung Cancer
por: Fu, Yang, et al.
Publicado: (2021)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

A Forgotten Corner in Cancer Immunotherapy: The Role of Lipids
por: Yu, Yang, et al.
Publicado: (2021)

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

CT-based radiomics in predicting pathological response in non-small cell lung cancer patients receiving neoadjuvant immunotherapy
por: Lin, Qian, et al.
Publicado: (2022)

Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response
por: Tian, Xi, et al.
Publicado: (2022)

Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
por: Tabchi, Samer, et al.
Publicado: (2017)

Risk Stratification of Cytogenetically Normal Acute Myeloid Leukemia With Biallelic CEBPA Mutations Based on a Multi-Gene Panel and Nomogram Model
por: Wu, Li-Xin, et al.
Publicado: (2021)

Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma
por: Zhu, Jun, et al.
Publicado: (2022)

Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases
por: Liu, Hao, et al.
Publicado: (2022)

Radiotherapy for head and neck tumours using an oral fixation and parameter acquisition device and TOMO technology: a randomised controlled study
por: Zhang, Xiaofang, et al.
Publicado: (2021)

Corrigendum: Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy
por: Liu, Xiangjun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gp4jlej4s2r0nk71eoe68pi9tt